See the DrugPatentWatch profile for teflaro

Teflaro, a antibiotic medication used to treat certain bacterial infections, is manufactured by the pharmaceutical company, AbbVie. The drug's patent is set to expire in the near future, which will likely have a significant impact on AbbVie.

Once a drug's patent expires, other companies are able to produce and sell generic versions of the medication. This increased competition typically leads to a decrease in the price of the drug, as generic versions are usually less expensive than the brand-name counterpart. As a result, the revenue generated by the original manufacturer, in this case AbbVie, will likely decrease.

According to DrugPatentWatch.com, Teflaro's patent is set to expire in December 2028 [1]. This means that other companies will be able to begin producing and selling generic versions of the drug as early as December 2028. This increased competition will likely result in a decrease in the price of Teflaro, and subsequently, a decrease in revenue for AbbVie.

It's worth noting that the exact impact of the patent expiration on AbbVie is difficult to predict, as it will depend on various factors such as the number of companies that choose to produce generic versions of Teflaro, the price at which they sell the drug, and the demand for Teflaro. However, it is expected that the patent expiration will have a negative impact on AbbVie's revenue.

In summary, the expiration of Teflaro's patent will likely have a negative impact on AbbVie's revenue due to increased competition and decreased prices of the drug.

Sources:
[1] <https://www.drugpatentwatch.com/drugs/teflaro>